ISU Abxis Co. Ltd Net Assets
ISU Abxis Co. Ltd net assets. Based on the latest financial reports, ISU Abxis Co. Ltd (086890) has net assets worth ₩120.39 Billion KRW (≈ $81.59 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩165.68 Billion ≈ $112.28 Million USD) and total liabilities (₩45.29 Billion ≈ $30.69 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 086890 year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩120.39 Billion |
| % of Total Assets | 72.67% |
| Annual Growth Rate | 19.2% |
| 5-Year Change | 131.47% |
| 10-Year Change | 116.49% |
| Growth Volatility | 52.99 |
Net Assets of ISU Abxis Co. Ltd (2014–2024)
Net assets of ISU Abxis Co. Ltd from 2014 to 2024. This chart illustrates how ISU Abxis Co. Ltd's net assets have evolved over time, based on quarterly financial data. See debt-free asset ratio of ISU Abxis Co. Ltd to measure how much of total assets are equity-financed.
Annual Net Assets for ISU Abxis Co. Ltd (2014–2024)
The table below shows the annual net assets of ISU Abxis Co. Ltd from 2014 to 2024. For live market cap and overall valuation, see how much is ISU Abxis Co. Ltd worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩100.86 Billion ≈ $68.35 Million |
+30.67% |
| 2023-12-31 | ₩77.19 Billion ≈ $52.31 Million |
+19.84% |
| 2022-12-31 | ₩64.41 Billion ≈ $43.65 Million |
-10.48% |
| 2021-12-31 | ₩71.95 Billion ≈ $48.76 Million |
+65.12% |
| 2020-12-31 | ₩43.57 Billion ≈ $29.53 Million |
-21.04% |
| 2019-12-31 | ₩55.18 Billion ≈ $37.40 Million |
-7.62% |
| 2018-12-31 | ₩59.73 Billion ≈ $40.48 Million |
-3.73% |
| 2017-12-31 | ₩62.05 Billion ≈ $42.05 Million |
+36.14% |
| 2016-12-31 | ₩45.58 Billion ≈ $30.89 Million |
-2.17% |
| 2015-12-31 | ₩46.59 Billion ≈ $31.57 Million |
+167.63% |
| 2014-12-31 | ₩17.41 Billion ≈ $11.80 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to ISU Abxis Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6411256686000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
ISU Abxis Co. Ltd Net Assets Breakdown (December 2024)
ISU Abxis Co. Ltd net assets breakdown by equity component as of December 2024.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩17.95 Billion | 17.80% |
| Other Components | ₩178.50 Billion | 176.98% |
| Total Equity | ₩100.86 Billion | 100.00% |
ISU Abxis Co. Ltd Competitors by Market Cap
The table below lists competitors of ISU Abxis Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Clime Capital Ltd
AU:CAM
|
$62.38 Million |
|
abrdn Asia Pacific Income Fund VCC
TO:FAP
|
$62.38 Million |
|
Africa Energy Corp
V:AFE
|
$62.39 Million |
|
Titanium Oyj
HE:TITAN
|
$62.41 Million |
|
Fine Blanking & Tool Co Ltd
TWO:4535
|
$62.34 Million |
|
Razor Labs Ltd
TA:RZR
|
$62.33 Million |
|
Gopeng Bhd
KLSE:2135
|
$62.30 Million |
|
Sheetal Cool Products Limited
NSE:SCPL
|
$62.30 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ISU Abxis Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 77,187,682,500 to 100,863,326,760, a change of 23,675,644,260 (30.7%).
- Net income of 14,718,030,800 contributed positively to equity growth.
- Other factors increased equity by 8,957,613,460.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩14.72 Billion | +14.59% |
| Other Changes | ₩8.96 Billion | +8.88% |
| Total Change | ₩- | 30.67% |
Book Value vs Market Value Analysis
This analysis compares ISU Abxis Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.23x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.57x to 1.23x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩2193.84 | ₩3455.00 | x |
| 2017-12-31 | ₩2486.02 | ₩3455.00 | x |
| 2018-12-31 | ₩2243.52 | ₩3455.00 | x |
| 2019-12-31 | ₩2072.57 | ₩3455.00 | x |
| 2020-12-31 | ₩1541.65 | ₩3455.00 | x |
| 2021-12-31 | ₩2168.31 | ₩3455.00 | x |
| 2022-12-31 | ₩1941.10 | ₩3455.00 | x |
| 2023-12-31 | ₩2230.13 | ₩3455.00 | x |
| 2024-12-31 | ₩2809.32 | ₩3455.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ISU Abxis Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 14.59%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 24.42%
- • Asset Turnover: 0.38x
- • Equity Multiplier: 1.59x
- Recent ROE (14.59%) is above the historical average (-17.66%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -64.32% | -157.78% | 0.14x | 2.81x | ₩-12.94 Billion |
| 2015 | -20.98% | -85.20% | 0.16x | 1.50x | ₩-14.43 Billion |
| 2016 | -4.47% | -10.70% | 0.32x | 1.31x | ₩-6.60 Billion |
| 2017 | -14.07% | -44.86% | 0.25x | 1.25x | ₩-14.93 Billion |
| 2018 | -21.74% | -77.57% | 0.24x | 1.17x | ₩-18.96 Billion |
| 2019 | -32.29% | -84.76% | 0.23x | 1.68x | ₩-23.33 Billion |
| 2020 | -45.59% | -77.58% | 0.31x | 1.90x | ₩-24.22 Billion |
| 2021 | 1.15% | 2.96% | 0.19x | 2.10x | ₩-6.37 Billion |
| 2022 | -11.25% | -17.60% | 0.30x | 2.13x | ₩-13.69 Billion |
| 2023 | 4.68% | 6.65% | 0.26x | 2.68x | ₩-4.11 Billion |
| 2024 | 14.59% | 24.42% | 0.38x | 1.59x | ₩4.63 Billion |
Industry Comparison
This section compares ISU Abxis Co. Ltd's net assets metrics with peer companies in the Pharmaceuticals industry.
Industry Context
- Industry: Pharmaceuticals
- Average net assets among peers: $101,034,626,727
- Average return on equity (ROE) among peers: 12.99%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ISU Abxis Co. Ltd (086890) | ₩120.39 Billion | -64.32% | 0.38x | $62.34 Million |
| Sam Chun Dang Pharm. Co. Ltd (000250) | $266.11 Billion | -4.10% | 0.95x | $2.49 Billion |
| DongKoo Bio & Pharma Co. Ltd. (006620) | $2.55 Billion | 158.01% | 22.83x | $21.80 Million |
| NatureCell Co.Ltd (007390) | $13.75 Billion | 13.78% | 0.78x | $793.12 Million |
| Sam-A Pharm. Co. Ltd (009300) | $200.47 Billion | 10.66% | 0.15x | $56.13 Million |
| Kyung Dong Pharmaceutical Co. Ltd (011040) | $259.82 Billion | 4.88% | 0.12x | $78.42 Million |
| WooGene B&G Co. Ltd (018620) | $27.27 Billion | -46.89% | 2.12x | $46.98 Million |
| Oscotec Inc (039200) | $21.78 Billion | -9.28% | 0.67x | $674.16 Million |
| EstechPharma Co. Ltd (041910) | $115.63 Billion | 3.31% | 0.05x | $42.90 Million |
| Komipharm International Co. Ltd (041960) | $60.02 Billion | -6.63% | 0.98x | $343.99 Million |
| Eagle Veterinary Technology Co.Ltd (044960) | $42.95 Billion | 6.15% | 0.28x | $25.96 Million |
About ISU Abxis Co. Ltd
ISU Abxis Co., Ltd., a biopharmaceutical company, develops and markets products for the treatment of cancer and rare diseases worldwide. The company offers Abcertin, an imiglucerase for injection that is used as long-term enzyme replacement therapy in patients with a confirmed diagnosis of Type 1 Gaucher disease; Fabagal, an agalsidase beta for injection, which is used as a long term enzyme repla… Read more